Cannabis Giant Tilray Medical Eyes U.S. Expansion As Federal Cannabis Policy Shifts

Tilray Brand Inc.’s (NASDAQ: TLRY) (TSX: TLRY) division Tilray Medical is advancing its medical cannabis operations in the U.S.

The formation of Tilray Medical USA, Inc., is in response to President Donald Trump issuing an executive order on Thursday to reclassify cannabis under federal drug laws. The executive order directs the Department of Justice to wrap up a rulemaking process introduced during the Biden administration to move marijuana from Schedule I of the Controlled Substances Act to Schedule III.

Irwin D. Simon, chairman and CEO of Tilray Brands, backed Trump’s decision to reschedule cannabis.

“This action aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity,” Simon said. “It also signals a future shaped by innovation, responsible oversight, and evidence-based policy. We believe this landmark decision is a significant catalyst for positive change within the health, wellness, and business communities across the U.S. and a critical, incremental step toward descheduling and comprehensive regulation.”

Tilray Medical has built its global presence in federally regulated markets via collaboration with regulators, physicians, hospitals and research institutions.

“Tilray has dedicated years to developing the necessary infrastructure, scientific knowledge, and regulatory skills to operate responsibly in federally legal medical cannabis markets,” Simon continued.

Tilray serves more than 500,000 patients worldwide, at the moment, with over 200 registered medical cannabis products and participating in more than 15 medical studies and clinical trials.

“As U.S. policies evolve, we’re prepared to engage thoughtfully and in full compliance – just as we have led in over 20 international medical cannabis markets,” Simon said. “We believe we are well-positioned to take the lead as we have the experienced team in place and remain committed to supporting the development and growth of a research-focused federal medical cannabis industry in the U.S.”